ADVANCED COLORECTAL CANCER

This phase 2 trial is testing whether adding two immune-boosting drugs (ongericimab and toripalimab) to standard second-line chemotherapy can shrink tumors in people with advanced MSS/pMMR colorectal cancer. The study enrolls 32 adults whose cancer progressed after first-line tre…

This early-phase trial tests a new drug called CBI-1214 in 80 people with advanced colorectal cancer that has not responded to standard treatments. CBI-1214 is designed to connect the body's own immune T cells to cancer cells, helping the immune system attack the tumor. The main …

This phase 2 trial tests whether a combination of three drugs—avutometinib, defactinib, and cetuximab—can help control advanced colorectal cancer that has stopped responding to standard anti-EGFR treatment. About 33 participants will receive the drugs orally and intravenously. Th…

This phase 2 trial is testing a combination of three drugs (liposomal irinotecan, capecitabine, and enlonstobart) plus a short course of radiation before surgery for people with locally advanced rectal cancer. The goal is to see if this approach can completely eliminate the tumor…

This Phase 2a trial tests an experimental drug called RBS2418 in 150 adults with advanced, metastatic colorectal cancer that has worsened despite standard treatments. The drug is designed to help the immune system recognize and attack cancer cells. Participants will receive eithe…

This early-phase trial is testing an experimental drug called 7MW4911 in 200 people with advanced colorectal or other gastrointestinal cancers that have progressed after standard treatments. The main goals are to find a safe dose and to see if the drug can shrink tumors. It is th…

This Phase 2 trial is testing whether a new drug called TL938, taken as a pill, combined with the targeted therapy trastuzumab (given by IV), can shrink tumors in people with HER2-positive colorectal cancer that has spread or come back. The study will enroll 80 adults who have al…

This study tests a new therapy called GT307, which uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack advanced colorectal cancer. The trial enrolls 18 adults whose cancer has worsened after first-line chemotherapy. The main goals are to check safety and …

This study tests a new first-line treatment for people with advanced colorectal cancer that cannot be removed by surgery or has spread. The treatment combines two drugs, levozolinate and 5-FU, given together through an IV. The goal is to see if this approach helps control the can…

This early-stage study tests a new drug called NM6603 in about 30 adults with advanced solid tumors (mainly colorectal or triple-negative breast cancer) who have run out of standard options. The main goal is to find the safest dose and check how the drug moves through the body. P…

This study tests whether taking an inactivated (killed) form of the bacterium Bacteroides fragilis can prevent diarrhea caused by chemotherapy. The trial will enroll 200 cancer patients about to start chemotherapy regimens known to cause diarrhea. Participants will receive either…

This study is testing whether growing a patient's tumor cells in the lab (as 3D 'organoids') can help doctors pick the best drug for advanced cancers that have stopped responding to standard treatments. About 152 adults with colorectal or pancreatic cancer will have a biopsy to c…

This study is testing whether using a blood test (liquid biopsy) to monitor treatment response can help people with advanced colorectal cancer maintain a better quality of life. Instead of relying only on CT scans, doctors will use the blood test to adjust treatment earlier and m…